Difference between revisions of "Thrombocytopenia in liver disease"
Jump to navigation
Jump to search
(→Regimen ) Tag: visualeditor-switched |
|||
| Line 1: | Line 1: | ||
{| class="wikitable" style="text-align:center; width:100%;" | {| class="wikitable" style="text-align:center; width:100%;" | ||
| − | !colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editors''' | + | ! colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354" |'''Section editors''' |
|- | |- | ||
| − | |style="background-color:#F0F0F0; width:15%"|[[File:Shruti.jpg|frameless|upright=0.3|center]] | + | | style="background-color:#F0F0F0; width:15%" |[[File:Shruti.jpg|frameless|upright=0.3|center]] |
| − | |style="width:35%"|<big>[[User:Shrutichaturvedi|Shruti Chaturvedi, MBBS, MSCI]]<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn] | + | | style="width:35%" |<big>[[User:Shrutichaturvedi|Shruti Chaturvedi, MBBS, MSCI]]<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn] |
| − | |style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]] | + | | style="background-color:#F0F0F0; width:15%" |[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]] |
| − | |style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Nashville, TN</big> | + | | style="width:35%" |<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Nashville, TN</big> |
|- | |- | ||
|} | |} | ||
| Line 27: | Line 27: | ||
! Study !! Evidence !! Comparator !! Efficacy | ! Study !! Evidence !! Comparator !! Efficacy | ||
|- | |- | ||
| − | | ADAPT-1 || Phase III || Placebo || Superior RR | + | | [https://www.ncbi.nlm.nih.gov/pubmed/29778606 ADAPT-1] || Phase III || Placebo || Superior RR |
|- | |- | ||
| − | | ADAPT-2 || Phase III || Placebo || Superior RR | + | | [https://www.ncbi.nlm.nih.gov/pubmed/29778606 ADAPT-2] || Phase III || Placebo || Superior RR |
|} | |} | ||
====Therapy==== | ====Therapy==== | ||
Revision as of 14:22, 24 May 2018
| Section editors | |||
|---|---|---|---|
 |
Shruti Chaturvedi, MBBS, MSCI Baltimore, MD |
 |
Benjamin Tillman, MD Nashville, TN |
See the thrombocytopenia reference page for general definitions and workup recommendations.
2 regimens on this page
2 variants on this page
|
Thrombocytopenia in liver disease with planned procedure
Avatrombopag monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| ADAPT-1 | Phase III | Placebo | Superior RR |
| ADAPT-2 | Phase III | Placebo | Superior RR |
Therapy
- Avatrombopag (Doptelet) as follows:
- Platelet count less than 40 x 109/L: 60 mg PO once per day on days 1 to 5
- Platelet count at least 40 and less than 50 x 109/L: 40 mg PO once per day on days 1 to 5
Procedure days were days 10 to 13